Buprenorphine implants in medical treatment of opioid addiction

References

• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000.
   Google Scholar
• Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. 2015. ( NSDUH Series H-50; HHS Publication No. SMA 15-4927). [cited 2017 Mar 3]. Available from: http://www.samhsa.gov/data/
   Google Scholar
• Center for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, Mortality File. Number and Age-Adjusted Rates of Drug-poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 2000–2014. Atlanta (GA): Center for Disease Control and Prevention; 2015. Available from: http://www.cdc.gov/nchs/data/health_policy/AADR_drug_poisoning_involving_OA_Heroin_US_2000-2014.pdf
   Google Scholar
• Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone – Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–444.
   PubMed Web of Science ®Google Scholar
• Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59(10):1411–1419.
   PubMed Web of Science ®Google Scholar
• Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–958.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–1513.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209.
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003–2011.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–1246.
   PubMed Web of Science ®Google Scholar
• Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93(4):515–532.
   PubMed Web of Science ®Google Scholar
• Gowing LR, Farrell M, Bornemann R, et al. Brief report: methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med. 2006;21(2):193–195.
   PubMed Web of Science ®Google Scholar
• Tsui JI, Evans JL, Lum PJ, et al. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974–1981.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
   PubMed Web of Science ®Google Scholar
• Fareed A, Vayalapalli S, Stout S, et al. Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis. 2011;30(1):27–38.
   PubMed Web of Science ®Google Scholar
• Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353(9148):221–226.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004;3:CD002207.
   Google Scholar
• Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2004. ( Treatment Improvement Protocal (TIP) Series 40; DHHS Publication No. SMA 04-3939). Available from: http://www.ncbi.nlm.nih.gov/books/NBK64245/pdf/Bookshelf_NBK64245.pdf
   Google Scholar
• Thomas CP, Fullerton CA, Kim M, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158–170.
   PubMed Web of Science ®Google Scholar
• Winstock AR, Lea T, Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int J Drug Policy. 2008;19(6):450–458.
   PubMed Web of Science ®Google Scholar
• Yokell MA, Zaller ND, Green TC, et al. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4(1):28–41.
   PubMedGoogle Scholar
• Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315–326.
   PubMed Web of Science ®Google Scholar
• Larance B, Lintzeris N, Ali R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend. 2014;136:21–27.
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat. 2014;47(1):27–34.
   PubMed Web of Science ®Google Scholar
• Wright N, D’Agnone O, Krajci P, et al. Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience. J Public Health (Oxf). 2016;38(3):e368–e374.
   PubMed Web of Science ®Google Scholar
• Reimer J, Wright N, Somaini L, et al. The impact of misuse and diversion of opioid substitution treatment medicines: evidence review and expert consensus. Eur Addict Res. 2016;22(2):99–106.
   PubMed Web of Science ®Google Scholar
• Bailey JE, Campagna E, Dart RC, et al. The underrecognized toll of prescription opioid abuse on young children. Ann Emerg Med. 2009;53(4):419–424.
   PubMed Web of Science ®Google Scholar
• Boyer EW, McCance-Katz EF, Marcus S. Methadone and buprenorphine toxicity in children. Am J Addict. 2010;19(1):89–95.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Emergency department visits and hospitalizations for buprenorphine ingestion by children – United States, 2010–2011. MMWR Morb Mortal Wkly Rep. 2013;62(3):56.
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011.
   PubMed Web of Science ®Google Scholar
• Tkacz J, Severt J, Cacciola J, et al. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am J Addict. 2012;21(1):55–62.
   PubMed Web of Science ®Google Scholar
• PROBUPHINE® (buprenorphine) implant for subdermal administration. Full prescribing information. Princeton (NJ): Braeburn Pharmaceuticals; 2016.
   Google Scholar
• Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science. 1980;207(4431):657–659.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267(20):2750–2755.
   PubMed Web of Science ®Google Scholar
• Bridge TP, Fudala PJ, Herbert S, et al. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend. 2003;70(2 Suppl):S79–85.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Larance B, Degenhardt L, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;5:CD011117.
   Google Scholar
• Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2005. ( Treatment Improvement Protocal (TIP) Series 43; HHS Publication No. SMA 12-4214). Available from: http://store.samhsa.gov/shin/content//SMA12-4214/SMA12-4214.pdf
   Google Scholar
• Hser YI, Evans E, Grella C, et al. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015;23(2):76–89.
   PubMed Web of Science ®Google Scholar
• SUBOXONE® (buprenorphine HCl and naloxone HCl dihydrate sublingual tablets) and SUBUTEX® (buprenorphine HCl sublingual tablets). Full prescribing information. Richmond (VA): Reckitt Benckiser Pharmaceuticals; 2013.
   Google Scholar
• SUBOXONE® (buprenorphne and naloxone) sublingual film for sublingual or buccal use. Full prescribing information. Richmond (VA): Indivior; 2015.
   Google Scholar
• Avdeef A, Barrett DA, Shaw PN, et al. Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates. J Med Chem. 1996;39(22):4377–4381.
   PubMed Web of Science ®Google Scholar
• Huestis MA, Cone EJ, Pirnay SO, et al. Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. Drug Alcohol Depend. 2013;131(3):258–262.
   PubMed Web of Science ®Google Scholar
• Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2011;12(Suppl 2):S26–35.
   PubMed Web of Science ®Google Scholar
• Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001;297(2):688–695.
   PubMed Web of Science ®Google Scholar
• Rosenthal RN, Lofwall MR, Kim S, et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA. 2016;316(3):282–290.
   PubMed Web of Science ®Google Scholar
• Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010;304(14):1576–1583.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. PROBUPHINE (buprenorphine HCl) implant CIII, briefing document for the FDA advisory committee, NDA 204442. [ meeting date 2015 Dec 11]. [cited 2017 Mar 3]. Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM480733.pdf
   Google Scholar
• Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013;108(12):2141–2149.
   PubMed Web of Science ®Google Scholar
• Dammerman R, Bailey GL, Beebe KL, et al. Long-term buprenorphine implants for treatment of opioid dependence: safety outcomes from two open-label extension trials. J Addict Behav Ther Rehabil. 2017;6(1). DOI: 10.4172/2324-9005.1000162
   Google Scholar